张思龙简介

【个人简介】

张思龙，男，理学博士，一流学科特聘教授A类，硕士生导师，主要从事靶点结构的小分子药物设计、合成及早期成药性评价研究。重点开展了基于外源性机制的蛋白降解剂和小分子靶向抑制剂的研究工作，近三年作为第一作者/通讯作者已发表论文20余篇，其中中科院一区文章12篇，包括药化顶级top1期刊J Med Chem 8篇。目前主持国家自然科学基金1项。

邮箱：silongzhang@whu.edu.cn

【主持项目】

1.国家自然科学青年基金项目，单线态氧介导的可控化雌激素受体α光敏降解剂的构建及其抗乳腺癌活性研究，2023/01-2025/12，30万；；

2.贵州大学自然科学专项（特岗）科研基金项目，基于化学降解机制的SOS1降解剂的构建、作用媒介的探究及其抗肿瘤活性研究，2023/07-2027/07，80万；

【学术论文】

1.Qing L. L.^#; Yu Q. Y.^#; Wang C. Q.; Lu X.; Yang Y. L.; Chen X.; Li X. X.; Min J.; Pan W. D.; He H. *; Zhang H. *;Zhang S.L.*. Discovery of D‑ring-contracted artemisinin as a potent hydrophobic tag for targeted protein degradation.J. Med. Chem.2025,68, 1619-1631.

2.Qing L. L.; Cheng Z, Z.; Xu J.; Wang Z. W.; Li Y. Y.; Gauthier M.;Zhang S.L.*; He H.*. Novel potent SOS1 inhibitors containing a tricyclic quinazoline scaffold: A joint view of experiments and simulations.Eur.J. Med. Chem.2025,282, 117065.

3.Lu X.; Wang Z. W.; Zhang Y.; Meng T.; Chen X. H.; Yuan R. Y.; Liu B.; He H.*; Ding X.*;Zhang S.L.*. A curcumin-based HDACs inhibitor for targeted sonodynamic therapy of breast cancer.Int. J. Biol. Macromol.2025,287, 138616.

4.He H.; Wang Z. W.; Peng X. K.: Qing L. L.; Zhang Y.; Fu S. J.; Xu J.; Li Y. Y.*;Zhang S.L.*.Identification of a sonically activated degrader of methionine adenosyltransferase 2A by anin silicoapproach assisted with the hole−electron analysis.J. Med. Chem.2024,67,543-554.

5.Xu J.; Zhao A.; Chen D.; Wang J.; Ma J.; Qing L. L.; Li Y. Y.; Fang H. X.; He H.*; Pan W. D.*;Zhang S. L.*Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability.Eur.J. Med. Chem.2024,266, 116160.

6.Li Y. Y.; Sun M.; Yu J.; Jiang W.; Tian W.; Chen X.;Zhang S. L.*; He H.*. Design ofsonosensitizers integratedwith resveratrol motif for synergetic sonodynamic therapy and NF-κB transcription suppression of breast cancer.J. Med. Chem.2023,66,6149-6159.

7.He H.; Chen R. Q.; Wang Z. W.; Qing L. L.; Zhang Y.; Liu Y.; Pan W. D.*;Fang H. X.*;Zhang S. L.*. Design of orally-bioavailable tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR.Bioorg. Chem.2023,136,106536.

8.Zhang S. L.; Qing L. L.; Wang Z. W.; Zhang Y.; Li Y. Y.; Fang H. X.*; Liu Y.; He H.*. Design and structural optimization of methionine adenosyltransferase 2A (MAT2A) inhibitors with high in-vivo potency and oral bioavailability.J. Med. Chem.2023,66,4849-4867.

9.Zhang S. L.^#*; Li Y. Y.^#; Li T.; Zhang Y.; Li H. M.; Cheng Z. Z.; Peng N.; Liu Y.; Xu J. *; He H.*. Activable targeted protein degradation platform based on light-triggered singlet oxygen.J. Med. Chem.2022,65, 3632-3643.入选ESI“高被引论文”.

10.Zhang S.L.; Zhang Y.; Chen X.; Xu J.; Fang H. X.; Li Y. Y. *; Liu Y.*; He H.*. Design and structural optimization of orally-bioavailable SOS1 inhibitors for the treatment of KRAS-driven carcinoma.J. Med. Chem.2022,65(23), 15856-15877.

11.He H.; Zhang Y.; Xu J.; Li Y. Y.; Fang H. X. *; Liu Y. *;Zhang S. L.*. Discovery of orally-bioavailable SOS1 inhibitors for suppressing KRAS-driven carcinoma.J. Med. Chem.2022,65(19), 13158-13171.

12.Zhang, Y.; Ding, X.; Xie, F.; Gao, M. J.; Qiu, J. L.; Wang, Z. Y.; Qing, L. L.; Yan, J. Q.; Li, Y. Y.; Xu, J.; Jiao, Y. H.;Liu, Y.*; He H.*;Zhang, S. L.*.Targeted recruitment and degradation of estrogen receptor α by photothermal polydopamine nanoparticles for breast tumor ablation.Adv. Healthc. Mater.2022,11, 2200960.

13.Li T.; Zhang Y.; Wang Z. W.; Qing L. L.; Zhang L. J. Peng N.; Liu Y. *;Zhang S. L.*; He H.*. AIEgen based turn-on fluorescent probes of histone deacetylase 6 via restriction of molecular motion.Sensor Actuat. B-Chem.2022,364, 131882.

【授权专利】

1.张思龙；钟杭；何欢；潘卫东；卿罗龙；王昌琦；陈晓；吴昱萱；李香香；一种以青蒿素类似物作为疏水标签的靶向蛋白降解剂及其制备方法和应用，申请日期：2024-09-12，申请号：2024112728920。

2.张思龙；何欢；张彧；王子威；潘卫东；一种以亚甲基蓝类似物作为单线态氧靶向蛋白降解标签的2-（4-羟苯基）苯并噻酚类化合物及其应用，申请日期：2024-06-16，申请号：2024107720007。